Natco Pharma rallies up to 7% on strong growth in Q4 net profit

In its financial report for the fourth quarter and full financial year ended March 31, 2024, the pharma company reported a nearly 19% year-on-year rise in consolidated revenue from operations in Q4FY24 at ₹1,068.3 crore against ₹897.9 crore in the same quarter a year ago.

The company’s PAT(Profit After Tax) for the March quarter grew 40% YoY to ₹386.3 crore compared to ₹275.8 crore in the year-ago quarter.

The company’s EBITDA (earnings before interest, taxes, depreciation, and amortisation) for the March quarter grew more than 46% to ₹539.3 compared to ₹368.1 in the corresponding quarter of the preceding fiscal.

On a quarter-on-quarter basis, the company’s revenue from operations for the March quarter grew more than 41% from ₹758.6 crore in the December quarter. The company’s PAT grew more than 81% sequentially compared to ₹212.7 crore in the preceding quarter. The company’s EBITDA grew more than 76% QoQ from ₹305.1 crore in Q3FY24.

The pharmaceutical company’s revenue from operations for FY24 grew 47% to ₹3,998.8 crore compared to ₹2,707.1 crore in the preceding fiscal. The company’s PAT for FY24 grew 94% to ₹1,388.3 crore compared to ₹715.3 crore in FY23.

In FY24, EBITDA increased more than 80% to ₹1,879.5 crore on a year-on-year basis from ₹1,040.2 crore in FY23.

Natco Pharma’s shares were trading at ₹1,038 apiece, up 0.8%, on the NSE at 1:34 pm.